Johnson & Johnson announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra, or JNJ-2113, the first targeted oral peptide that selectively blocks the ...
Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced that it is ...
Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ETCompany ParticipantsMichael Bodner - Group President, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback